
The chief development officer at Clene Nanomedicine provided insight on why CNM-Au8, an investigational agent in development, has shown positive results across both multiple sclerosis and ALS. [WATCH TIME: 2 minutes]
The chief development officer at Clene Nanomedicine provided insight on why CNM-Au8, an investigational agent in development, has shown positive results across both multiple sclerosis and ALS. [WATCH TIME: 2 minutes]
The chief development officer at Clene Nanomedicine provided insight on the mechanistic function of CNM-Au8 and how it improves survival in patients with ALS. [WATCH TIME: 3 minutes]